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total costs may be much greater when the high levels of
post-acute care are fully captured.
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IS RESIDRONATE MORE COST-EFFECTIVE 
THAN ETIDRONATE FOR FRACTURE 
PREVENTION? A COST-UTILITY ANALYSIS
Iglesias C, Torgerson D
Centre for Health Economics and Department of Health 
Studies, University of York, York, UK
OBJECTIVE: Only hip protectors, calcium and vitamin
D therapy and bisphosphonates have been shown to re-
duce hip fractures with the latter having the more robust
evidence. Three bisphosphonate are currently widely avail-
able but at differing costs, we compared the cost-effec-
tiveness of the two least expensive compounds (etidr-
onate & residronate). METHODS: We used a Markov
model to compare costs and health states of 1000 women
aged 75 years with a prevalent vertebral fracture, and
treated with either etidronate or residronate for 3 years
and then followed through until aged 100 years. We as-
sumed treatment was only effective for the 3 years. Drug
costs were taken from MIMs, fracture costs were taken
from published estimates and uprated to 1999 prices,
with hip fracture incurring a cost of £13,000 in the first
year and £7,000 in the second year. Hip fractures were
assumed to be reduced by 58% as evidenced in the most
recent trial and 33% for non hip and non vertebral frac-
tures for the residronate treated group. For etidronate
observational data suggests that it reduces hip fractures
by 34% and non hip and non vertebral fractures by
20%. We also assumed a loss of 0.32 QALYs in the year
of fracture. RESULTS: Residronate was revealed as the
dominant therapy for treating women of 75 years with a
previous vertebral fracture. Estimates of total cost sav-
ings per patient with a moderate vertebral deformity
were £10,627 and £10,857 for residronate and etidro-
nate respectively. Similarly, QALYs per patient gained
were 7.58 and 7.56 for residronate and etidronate, re-
spectively. Sensitivity analysis confirmed the robustness
of residronate’s dominancy. CONCLUSION: In the base-
line analysis both treatments are cost saving. Residronate
even seems to be cost saving when compared with etidr-
onate. Thus, residronate therapy dominates etidronate,
that is it saves more costs and produces more QALYs.
N Charges* LOS LTC%
Other
Care**%
Overall 57,807 $8,082 5.6 34.3% 29.4%
50–64 4,116 $9,396 5.4 10.4% 24.5%
65–74 9,850 $8,661 5.5 23.0% 29.3%
75–84 24,321 $8,128 5.9 35.1% 31.0%
85 19,521 $7,455 5.7 44.2% 28.9%
*Updated to 2000 dollars by Medical Care component of CPI.
**Acute hospital, other facility, home care.
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OBJECTIVE: To determine the average annual cost of
treating carpal tunnel syndrome (CTS) in a managed care
population. METHODS: All subjects contained within
PharMetric’s Integrated Outcomes database possessing a
diagnosis of carpal tunnel syndrome (ETG  0174 or
0175) during 1996–1999 were eligible for study inclu-
sion. Patients were required to have 12 months of data
following the first (index) CTS diagnosis present. Patients
less than 18 years of age and greater than 90 years of age
were excluded. Carpal tunnel syndrome specific and total
pharmacy charges were captured for the study period.
RESULTS: 82,176 patients met the inclusion criteria.
The mean age was 46.5 years (SE  0.047), and 70.6%
of the sample was female. 82% of patients with CTS did
not require surgery. General practitioners/internal medi-
cine account for 73.0% of CTS diagnoses in a given year.
Before diagnosis, the mean annual CTS specific charges
per patient was $86.14 (SE  2.47). After diagnosis, the
mean annual CTS specific charges per patient was $1186.11
(SE  6.51). Post diagnosis, inpatient charges accounted
for 40.6% of CTS-related expenses, while outpatient and
pharmacy charges accounted for 55.5% and 1.7% re-
spectively. Oral steroid use increased slightly from
16.8% to 18.7% after diagnosis of CTS, while NSAID
use increased from 36.3% to 51.2%. Outpatient steroid
injections doubled from 5.7% to 11.9% after a diagnosis
of CTS. Soft tissue disorders and osteoarthritis were the
two comorbidities that occurred most frequently with a
diagnosis of CTS with 22.8% and 12.7%, respectively.
CONCLUSION: Patients in this study, once diagnosed
with CTS, noticed significantly increased medical ex-
penses, particularly outpatient charges. NSAIDs use and
outpatient steroid injections were the preferred modali-
ties of treatment once a diagnosis of CTS was made.
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OBJECTIVE: To examine health status factors associ-
ated with utilization of different types of antidiabetic
medication in managed-care enrolled older adults, and in
turn, to study the association between antidiabetic medi-
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cation utilization and overall health care service use.
METHODS: A prospective longitudinal cohort study em-
ploying robust multiple regression analyses was con-
ducted over a 2-year post-enrollment period in 762 man-
aged care enrolled diabetic older adults, for whom complete
prescription refill data were available. Patients completed
a comprehensive health risk screen measuring self-re-
ported health perception, falls, lifestyle, depressive symp-
tomatology, and pre-enrollment health care service use at
time of enrollment in the plan. We used the medication
possession ratio and total annual health care charges as
measures of post-enrollment antidiabetic medication and
health care service use. RESULTS: We found that in this
population, annual medication possession rates were
nearly 57% for oral hypoglycemics, as compared to ap-
proximately 40% for both insulin as well as insulin sensi-
tizers. Among antidiabetic medications, only insulin pos-
session decreased across time (P  0.05). Older adults
with increased number of diabetic medications, as well as
reporting to have had falls under utilized all antidiabetic
medications (P  0.05). Patients with increased age and
comorbidity under utilized insulin sensitizers (P  0.001).
Self-reported health status was predictive of total health
care service utilization in this population, but not antidia-
betic medication use. After controlling for the significant
effects of health status, comorbidity severity, and number
of medications, a 10% increase in the use of oral hy-
poglycemics was associated with a 3.5% decrease in total
annual non-prescription related health care charges (P 
0.001). CONCLUSION: There seem to be significant dif-
ferences in utilization patterns of different antidiabetic
medications in this older adult population, with a clear
decrease in health care service use associated with in-
creased utilization of oral hypoglycemics. Improving medi-
cation adherence could potentially reduce avoidable med-
ical costs in similar populations.
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OBJECTIVE: To assess the cost-effectiveness of a new
human dermal replacement (Dermagraft–D) compared with
current practice (CP). METHODS: A Markov model was
developed, to simulate the health status of a cohort of
100 patients with a diabetic foot ulcer, during 52 weeks.
The health states considered are: healed, same site recur-
rence, unhealed not infected, cellulitis, osteomyelitis, am-
putation and death. The set of transition probabilities is
derived directly from the US clinical trial. The costs of
each health state were estimated by a Delphi panel of dia-
betologists (direct costs only in a societal perspective).
RESULTS: The total number or ulcers healed is first ul-
cers healed (D: 76,38; median time to heal—MTH: 14–
15 weeks vs CP: 69,35, MTH: 28–29 weeks) plus recur-
rences which are subsequently healed within the 52-week
period (D: 25,24; MTH 3–4 weeks; CP: 14,29 MTH: 5–6
weeks) are significantly different. The average expected
cost per patient (C/E) with CP for the 52 weeks period
considered is 47,418 French Francs (FF) vs 54,384 FF for
D group (including 18.200 FF for D treatment and
36,184 FF of conventional treatment). Because D heals
more ulcers, the average cost per ulcer healed is lower
(53,522 FF vs 56,687 FF). The incremental cost-effective-
ness ratio of D (C/E) equals 387.84 FF. CONCLU-
SION: Human dermal replacement is cost-effective be-
cause it offers an opportunity to heal ulcers for less than
the price that is already paid by the collectivity, using
standard practice (56,687 FF).
PDB3
USE OF BOOTSTRAP IN A COST-OF-ILLNESS 
STUDY TO DERIVE ACCURACY OF ESTIMATES
Wagenpfeil S1, Stammer H2, Neiss A1, Reitberger U3, Goertz A2
1Institute for Medical Statistics and Epidemiology, Technical 
University Munich, Munich, Germany; 2SmithKline Beecham 
Pharmaceuticals, Munich, Germany; 3Kendle International Inc., 
Munich, Germany
OBJECTIVE: The CODE-2 study provided costs for pa-
tients with diabetes mellitus type 2 in Germany. The aim
of this analysis is to assess the accuracy of these esti-
mates. METHODS: The German arm of CODE-2 was
based on a representative sample of 809 diabetic patients.
Treatment strategies, resource use and costs were investi-
gated for the year 1998. Patients were grouped in 5 strata
based on their complication status, which was assumed
to be the main cost factor. Rare cost driver groups were
over-represented in order to obtain higher accuracy of es-
timates. For extrapolation on a population level, the re-
sults were weighted according to real prevalence data on
complications estimated in a pre-study. Results were cal-
culated as a weighted average from the mean in each stra-
tum. Because the degree of precision of these estimates
was not measurable with the usual statistical methods,
bootstrap estimates were computed for lower and upper
bounds of 95% confidence intervals taking 10,000 inde-
pendent bootstrap samples. RESULTS: Bootstrap esti-
mates were stable after 10,000 replicate samples. CON-
CLUSION: Bootstrap confidence intervals show a
remarkable accuracy of estimations performed in this
study. So combination of a weighted stratification by cost
factor followed by bootstrapping estimation is an appro-
priate method for analysing the average of highly vari-
able parameters such as costs of diabetes.
